CD274 and neoplasm: To elucidate the difference in the therapeutic performance of individual groups, we carried out comprehensive analysis on the pharmacokinetic behavior of individual components and found that most of anti-PD-L1 antibody reached the tumor site at 6 h, while BAY-876 were mainly enriched in the kidney site at 6 h (Supplementary Fig. 41d), as BAY-876 lacks intrinsic tumor targeting capacity and therefore failed to synchronize the antitumor actions of BAY-876 and immune checkpoint inhibiting antibodies.